Previous 10 | Next 10 |
SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underw...
Clinical-stage vaccine innovation company Vaxcyte ( NASDAQ: PCVX ) has priced its $600M securities offering. The underwritten public offering comprises 15M shares of common stock and pre-funded warrants to purchase 3,750,000 shares of common stock. The shares of common...
SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering...
Vaxcyte ( NASDAQ: PCVX ) on Monday announced an underwritten public offering of stock and pre-funded warrants. Underwriters will be given a 30-day option to buy up to an additional 15% of the number of shares in the offering. There can be no assurance as to whether or ...
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public o...
Vaxcyte ( NASDAQ: PCVX ) added ~70% intraday on Monday to reach the highest level since November 2020 after the clinical-stage vaccine developer announced promising data from a Phase 1/2 clinical study for its experimental 24-valent pneumococcal vaccine (PCV), VAX-24. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Tricida (NASDAQ: TCDA ) stock is falling on Monday following the release of poor results from a Phase 3 clinical trial . That trial covers the use of veverimer to treat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/PhotobyTawat Vaxcyte (NASDAQ: PCVX ) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. This part of the study hand...
Clinical-stage vaccine developer Vaxcyte, Inc. ( NASDAQ: PCVX ) jumped ~38% pre-market Monday after the company announced topline data from Phase 1/2 clinical proof-of-concept study for its experimental 24-valent pneumococcal conjugate vaccine (PCV), VAX-24. According to...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks is news out of China, an acquisition deal, as well as...
News, Short Squeeze, Breakout and More Instantly...
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Boa...
2024-06-23 20:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-23 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...